Tenet Healthcare Corporation (THC)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Tenet Healthcare Corporation.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 5 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 254.80 $ — 93% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 3.6% failed
- More than 10% revenue growth is expected for the coming year 1.6% failed
- Share count grows by less than 3% a year -6.3% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 15.0% failed
- Gross margin at 40% or higher and without meaningful erosion 82.3% passed
- Goodwill from acquisitions does not grow faster than revenue 37.7% passed
- Net debt below twice EBITDA 2.3 x EBITDA failed
- Operating cash flow covers the profits of the last three years 2,743 m passed
- Return on capital at 15% or higher, or up versus two years ago 13.6% passed
- Insiders hold at least 10% or are net buyers 1.1% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 8.9% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 22
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 21.07 | 18.50 – 21.65 | 22,434 | 25.6% | 18 |
| 12/31/2027 | 20.45 | 15.38 – 22.36 | 22,492 | -3.0% | 20 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 4.65 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 3.32 | 41.60 | 5,072 | -5.70 | 6.30 | -331 | -661 |
| 2025: Q1 | 4.27 | -80.00 | 5,223 | -2.70 | 7.80 | 815 | 642 |
| 2025: Q2 | 3.14 | 19.30 | 5,271 | 3.30 | 5.50 | 936 | 743 |
| 2025: Q3 | 3.86 | -21.00 | 5,289 | 3.30 | 6.50 | 1,058 | 778 |
| 2025: Q4 | 4.22 | 27.20 | 5,527 | 9.00 | 6.70 | 731 | 367 |
| 2026: Q1 | 8.01 | 87.60 | 5,368 | 2.80 | 13.10 | 1,641 | 1,461 |
| 2026: Q2 | 9.84 | 213.40 | 5,628 | 6.80 | 18.60 | 585 | 417 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 19,621 | 1,247 | -192 | -1.93 | 558 | 417 | 24,701 |
| 2017 | 19,179 | 1,113 | -704 | -7.00 | 1,200 | -147 | 23,385 |
| 2018 | 18,313 | 1,637 | 104 | 1.00 | 1,049 | -119 | 22,409 |
| 2019 | 18,479 | 1,537 | -215 | -2.08 | 1,233 | -371 | 23,351 |
| 2020 | 17,640 | 1,989 | 399 | 3.75 | 3,407 | 28 | 27,106 |
| 2021 | 19,485 | 2,871 | 914 | 8.42 | 1,568 | 1,028 | 27,579 |
| 2022 | 19,174 | 2,333 | 411 | 3.72 | 1,083 | 1,142 | 27,156 |
| 2023 | 20,548 | 2,510 | 611 | 5.83 | 2,374 | 1,608 | 28,312 |
| 2024 | 20,665 | 5,956 | 3,200 | 32.69 | 2,047 | 4,171 | 28,936 |
| 2025 | 21,310 | 3,439 | 1,407 | 15.49 | 3,540 | 4,220 | 29,677 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Tenet Healthcare Corporation ist ein diversifiziertes Gesundheitsdienstleistungsunternehmen in den USA. Das Unternehmen ist in zwei Segmenten tätig: Hospital Operations and Services sowie Ambulatory Care.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 77,000 |
| Headquarters | Dallas, TX |
| Address | 14201 Dallas Parkway, 75254 Dallas, United States |
| Phone | 469 893 2200 |
| Website | tenethealth.com |
| IPO Date | 4. Jan 1982 |
| ISIN | US88033G4073 |
| Stock Split | 1:4 on 10/11/2012 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Saumya Sutaria M.D. | Chairman & CEO | 1973 |
| Sun K. Park | Executive VP & CFO | 1976 |
| Lisa Y. Foo | Executive VP & Chief Operating Officer | 1991 |
| Paola M. Arbour | Executive VP & Chief Information Officer | 1964 |
| Thomas W. Arnst | EVP, Chief Administrative Officer, Chief Risk Officer, General Counsel & Corporate Secretary | 1963 |
| John Michael Grooms | Senior VP, Controller & Principal Accounting Officer | 1978 |
| William McDowell III | Vice President of Investor Relations | – |
| Jana Durfee | Senior VP & Chief Compliance Officer | – |
| Michael T. Maloney | Executive Vice President of Corporate Development | – |
| Clint Hailey | Chief Managed Care Officer & Senior VP | 1965 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 29. Jul 2026 | Foo Lisa Y | EVP, Chief Operating Officer | Sell | 10,000 | 258.03 | 2,580,300 |
| 27. Jul 2026 | Lynch Christopher S. | Director | Sell | 3,837 | 243.44 | 934,079 |
| 27. Jul 2026 | Arbour Paola M | EVP, Chief Information Officer | Sell | 10,878 | 243.90 | 2,653,144 |
| 27. Jul 2026 | Bierman James L | Director | Sell | 5,000 | 244.96 | 1,224,800 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.